Final analysis of a Multicenter Single-Arm Confirmatory Trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906

Author:

Nozaki Miwako1ORCID,Kagami Yoshikazu2,Machida Ryunosuke3,Nakamura Kenichi3,Ito Yoshinori2,Nishimura Yasumasa4,Teshima Teruki5,Saito Yoshihiro6,Nagata Yasushi7,Matsumoto Yasuo8,Akimoto Tetsuo9,Hiraoka Masahiro10,

Affiliation:

1. Department of Radiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan

2. Department of Radiation Oncology, Showa University School of Medicine, Tokyo, Japan

3. Department of International Clinical Development, JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan

4. Department of Radiation Oncology, Kindai University Hospital, Osaka, Japan

5. Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan

6. Division of Radiation Oncology, Saitama Cancer Center, Saitama, Japan

7. Department of Radiation Oncology, Hiroshima University Hospital, Hiroshima, Japan

8. Department of Radiation Oncology, Niigata Cancer Center Hospital, Niigata, Japan

9. Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Chiba, Japan

10. Department of Radiation Oncology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan

Abstract

Abstract Objective To evaluate the safety and efficacy of hypofractionated whole breast irradiation for Asian women after breast-conserving surgery. This is an updated report with 5-year follow-up. Methods and materials Asian women who had invasive breast cancer with clinical tumor size ≤3 cm, pN0-1c and negative inked margins were enrolled. Hypofractionated whole breast irradiation of 42.56 Gy/16 fractions was delivered, and boost irradiation of 10.64 Gy/4 fractions was added when the surgical margin was ≤5 mm. The primary endpoint was the proportion of grade ≥ 2 late adverse reactions within 3 years. Secondary endpoints included early adverse events, overall survival, disease-free survival, ipsilateral breast relapse-free survival, late adverse reactions and cosmetic outcome. Toxicities were evaluated using CTCAE ver3.0. Cosmetic outcomes were assessed using a 4-point scale and CTCAE ver3.0 for hyper/hypopigmentation, breast nipple/areolar deformity and breast volume/deformity. Results Between February 2010 and August 2012, 312 patients were enrolled, and 306 received hypofractionated whole breast irradiation. Median follow-up was 70.5 (range 7.6–88.9) months. The proportion of grade ≥ 2 late adverse reactions within 3 years was 4.3% (90% confidence interval 2.5–6.7%). Grade 2 early adverse events occurred in 38 (12.4%); none had grade 3/4. Five-year overall survival, disease-free survival and ipsilateral breast relapse-free survival were 98.7, 95.4 and 98.0%, respectively. Of the 304 evaluable patients, 29 (9.5%; 95% confidence interval 6.5–13.4%) had grade 2/3 late adverse reactions; none had grade 4/5. At 5 years, 70/289 (24.2%) showed any worsening of breast cosmetic changes. Conclusions Hypofractionated whole breast irradiation is considered a standard treatment for Asian women with margin-negative invasive breast cancer after breast-conserving surgery.

Funder

Health and Labour Sciences Research Grant for Clinical Cancer Research

Japanese Ministry of Health, Labour and Welfare

National Cancer Center Research and Development Fund

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3